


TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

3/25/2008; page 1

Suggested Formula	Sodium Chloride 0.9% Intravenous or Intramuscular Injection (Solution, 100 mL)	FIN	F 002 239
----------------------	--------------------------------------------------------------------------------	-----	-----------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC#	Supplier	Lot Number	Expiry Date
Sodium Chloride, USP	0.900	g				
Benzyl Alcohol, NF	1.0	mL				
Sterile Water For Injection, USP	90.0	mL		8		
Sterile Water For Injection, USP	q.s to 100.0	mL				





TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

3/25/2008; page 2

Suggested Formula Sodium Chloride 0.9% Intravenous or Intramuscular Injection (Solution, 100 mL) FIN F 002 239

SPECIAL PREPARATORY CONSIDERATIONS

ECIAL PREPARATORT CONSIL	DENATIONS	
Ingredient-Specific Information		
Light sensitive (protect from lig	ght whenever possible):	Benzyl Alcohol
Hygroscopic (protect from moi.	sture whenever possible):	Sodium Chloride, Benzyl Alcohol
Suggested Preparatory Guidelines		
Non-Sterile Preparati	ion Sterile Preparation	20,20
<u>Processing Error /</u> <u>Testing Considerations</u> :		sterility and endotoxin testing considerations during asure an additional 5 to 9% of the required quantities
Special Instruction:	This formula must be prepared with environmental conditions, following	ithin the appropriate facilities under adequate ing the necessary guidelines and procedures as stated qualified personnel must prepare this formula.
	All heat stable, reusable materials by dry heat sterilization at 250°C	s and equipment must be sterilized and depyrogenated for 2 hours prior to use.
	Every batch of final product compendotoxin tested before being disp	pounded using this procedure must be sterility and pensed.
		le gown, sterile gloves, shoe covers, head cap, lways be worn. In addition, proper personnel tering the buffer or clean area.
		by performing a filter stress test. If the test be defective, the solution must be discarded and
	1	f very small quantities of ingredients. All calculations be verified before dispensing the final product.

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. THE PHARMACIST IS ADVISED THAT THE SUGGESTED FORMULA IS PRESENTED AT A SPECIFIED STRENGTH AND QUANTITY, AND THAT ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. FURTHER, THE FORMULA SHOULD ONLY BE PROVIDED UPON THE REQUEST AND AUTHORIZATION OF A LICENSED PRESCRIBER. PHARMACISTS USING THIS SUGGESTED FORMULA ARE ADVISED THAT ITS USE AS A MEANS OF THERAPEUTIC INTERVENTION IS BASED ON THE PRESCRIBER'S INDEPENDENT CLINICAL JUDGEMENT AND THE PROFESSIONAL EXPERTISE OF THE PHARMACIST. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE PRECISE STABILITY OF THIS SUGGESTED FORMULA. NO CLAIMS ARE BEING MADE AS TO THE SAFETY OR CLINICAL EFFICACY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. FURTHERMORE, THE NETWORK, TAKES NO RESPONSIBILITY AND MAKES NO RECOMMENDATIONS IN DISPENSING THIS PRODUCT. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

3/25/2008; page 3

Suggested Formula	Sodium Chloride 0.9% Intravenous or Intramuscular Injection (Solution, 100 mL)	FIN	F 002 239
----------------------	--------------------------------------------------------------------------------	-----	-----------

SUGGESTED PREPARATION (for 100 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Sodium Chloride, USP §	0.900	g			
Benzyl Alcohol, NF §	1.0	mL	(S)		
Sterile Water For Injection, USP §	90.0	mL			
Sterile Water For Injection, USP §	q.s to 100.0	mL	0/40		

- * Takes into account increased batch size conversions and density conversions, if required.
- § Weigh / measure just prior to use.

	Preparatory Instruction
	IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique
1.	Equipment sterilization:
	Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.
2.	Medium preparation:
	A. Combine and mix the following ingredients together:
	- Benzyl Alcohol - Sterile Water For Injection (90.0 mL <i>plus</i> processing error adjustment)
	Specifications: Continuously mix.
	End result: Homogeneous liquid-like solution.

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. THE PHARMACIST IS ADVISED THAT THE SUGGESTED FORMULA IS PRESENTED AT A SPECIFIED STRENGTH AND QUANTITY, AND THAT ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. FURTHER, THE FORMULA SHOULD ONLY BE PROVIDED UPON THE REQUEST AND AUTHORIZATION OF A LICENSED PRESCRIBER. PHARMACISTS USING THIS SUGGESTED FORMULA ARE ADVISED THAT ITS USE AS A MEANS OF THERAPEUTIC INTERVENTION IS BASED ON THE PRESCRIBER'S INDEPENDENT CLINICAL JUDGEMENT AND THE PROFESSIONAL EXPERTISE OF THE PHARMACIST. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE PRECISE STABILITY OF THIS SUGGESTED FORMULA. NO CLAIMS ARE BEING MADE AS TO THE SAFETY OR CLINICAL EFFICACY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. FURTHERMORE, THE NETWORK, TAKES NO RESPONSIBILITY AND MAKES NO RECOMMENDATIONS IN DISPENSING THIS PRODUCT. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.



Suggested

MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

3/25/2008; page 4

F 002 239

FIN

Sodium Chloride 0.9% Intravenous or Intramuscular Injection (Solution, 100 mL) Formula **Powder to medium integration:** A. Incrementally add the Sodium Chloride to the following mixture: -Homogeneous liquid-like solution (Step 2A) Specifications: Continuously mix, until all solid particles have completely dissolved. End result: Homogeneous liquid-like solution. **Filling to volume:** A. Add additional Sterile Water For Injection to the mixture (Step 3A) to fill to the required batch size (100.0 mL plus processing error adjustments). Specifications: Continuously mix. End result: Homogeneous liquid-like solution. 5. Filtering and transferring:

7. **Sterility testing:**

6.

Filter integrity test:

sample for sterility and endotoxin testing.

solution must be discarded and remade.

Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.

Validate filter integrity by performing a filter stress test. If the test demonstrates that the filter might be defective, the

Aseptically filter the solution through a 0.22-um sterile filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the Test

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. THE PHARMACIST IS ADVISED THAT THE SUGGESTED FORMULA IS PRESENTED AT A SPECIFIED STRENGTH AND QUANTITY, AND THAT ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. FURTHER, THE FORMULA SHOULD ONLY BE PROVIDED UPON THE REQUEST AND AUTHORIZATION OF A LICENSED PRESCRIBER. PHARMACISTS USING THIS SUGGESTED FORMULA ARE ADVISED THAT ITS USE AS A MEANS OF THERAPEUTIC INTERVENTION IS BASED ON THE PRESCRIBER'S INDEPENDENT CLINICAL JUDGEMENT AND THE PROFESSIONAL EXPERTISE OF THE PHARMACIST. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE PRECISE STABILITY OF THIS SUGGESTED FORMULA. NO CLAIMS ARE BEING MADE AS TO THE SAFETY OR CLINICAL EFFICACY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. FURTHERMORE, THE NETWORK, TAKES NO RESPONSIBILITY AND MAKES NO RECOMMENDATIONS IN DISPENSING THIS PRODUCT. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

3/25/2008; page 5

Suggested Formula	Sodium Chloride 0.9% Intravenous or Intramuscular Injection (Solution, 100 mL)	FIN	F 002 239	
----------------------	--------------------------------------------------------------------------------	-----	-----------	--

SUGGESTED PRESENTATION

GGESTED PRI	_JL	NIATION	_		
Estima Beyond-Use D		14 days, refrigerated. BUD based on a successful sterility and endotoxin test result.	Packag Requireme		Sterile, unit dose injection vials.
	1	Use as directed. Do not exceed dose.	d prescribed	5	Keep refrigerated. Do not freeze.
Auxiliary Labels	2	Discard container after use.		6	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.
	3	Discard in the presence of matter.	particulate	7	Do not use if discolored.
	4	Keep out of reach of children.			
Pharmacist Instructions	Ad	d any auxiliary labels specific to t	he API to the	disp	ensing container as deemed necessary.
Patient Instructions	(contact your pharmacist in the event of adverse reactions				

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. THE PHARMACIST IS ADVISED THAT THE SUGGESTED FORMULA IS PRESENTED AT A SPECIFIED STRENGTH AND QUANTITY, AND THAT ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. FURTHER, THE FORMULA SHOULD ONLY BE PROVIDED UPON THE REQUEST AND AUTHORIZATION OF A LICENSED PRESCRIBER. PHARMACISTS USING THIS SUGGESTED FORMULA ARE ADVISED THAT ITS USE AS A MEANS OF THERAPEUTIC INTERVENTION IS BASED ON THE PRESCRIBER'S INDEPENDENT CLINICAL JUDGEMENT AND THE PROFESSIONAL EXPERTISE OF THE PHARMACIST. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE PRECISE STABILITY OF THIS SUGGESTED FORMULA. NO CLAIMS ARE BEING MADE AS TO THE SAFETY OR CLINICAL EFFICACY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. FURTHERMORE, THE NETWORK, TAKES NO RESPONSIBILITY AND MAKES NO RECOMMENDATIONS IN DISPENSING THIS PRODUCT. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

3/25/2008; page 6

Suggested Formula	Sodium Chloride 0.9% Intravenous or Intramuscular Injection (Solution, 100 mL)	FIN	F 002 239
----------------------	--------------------------------------------------------------------------------	-----	-----------

REFERENCES

1.	USP <797> Pharmaceutical Compounding – Sterile Preparations. US Pharmacopeial Convention, Inc. <i>United States Pharmacopeia XXVIII / National Formulary 23</i> . Rockville, MD. 2004: 2461.
2.	Sodium Chloride. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 4th Edition</i> . American Pharmaceutical Association; 2003: 556.
3.	Benzyl Alcohol. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients</i> , 4 th Edition. American Pharmaceutical Association; 2003: 53.
4.	Sodium Chloride (Monograph). <i>United States Pharmacopeia XXVIII / National Formulary 23</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2004: 2840.
5.	Benzyl Alcohol (Monograph). <i>United States Pharmacopeia XXVIII / National Formulary 23</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2004: 2965.

